"This may well indicate that the FDA has raised the hurdle on safety aspects of cholesterol-lowering agents compared with what it was, " says Evan Stein, director of the Metabolic and Atherosclerosis Research Center in Cincinatti.

FORBES: The Heart Drug Junkyard